Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

LDK378 Compassionate Use for Treating Carcinomatous Meningitis in an ALK Translocated Non–Small-Cell Lung Cancer

LDK378 Compassionate Use for Treating Carcinomatous Meningitis in an ALK Translocated... Case Repotr LDK378 Compassionate Use for Treating  Carcinomatous Meningitis in an ALK Translocated  Non–Small-Cell Lung Cancer Jennifer Arrondeau,* Samy Ammari,† Benjamin Besse,‡ and Jean-Charles Soria§ 42-year-old woman, never smoker, complaining of chronic treated with crizotinib. Crizotinib is a potent, small molecule Acough, underw   ent computed tomography that depicted oral inhibitor of ALK, which has shown efficacy in ALK- a right lower lung mass and subcarinal lymphadenopathy. rearranged NSCLC with an overall response rate (ORR) of Disease was classified as stage IIIA lung adenocarcinoma 60.8% and a median progression-free survival duration of 9.7 2 3 (cT3N2M0), without an EGFR or KRAS mutation. After neo- months. ORR to crizotinib is only 25% in brain metastasis. adjuvant chemotherapy with cisplatin and gemcitabine, the The central nervous system (CNS) remains the dominant site patient underwent surgery comprising a right pneumonectomy of acquired resistance on therapy for ALK patients with or and a lymph node dissection. One year and a half later, she was without brain metastasis. LDK378 (Novartis) is a new potent diagnosed with liver metastasis. The patient was treated with and selective oral ALK inhibitor. Tumor regression has been carboplatin, pemetrexed, and bevacizumab, achieving a stable observed in ALK-positive NSCLC xenografts and even in disease for 9 months. Fluorescence in situ hybridization http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

LDK378 Compassionate Use for Treating Carcinomatous Meningitis in an ALK Translocated Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology , Volume 9 (8) – Aug 1, 2014

Loading next page...
 
/lp/wolters-kluwer-health/ldk378-compassionate-use-for-treating-carcinomatous-meningitis-in-an-G0M9WpKkPj

References (4)

Copyright
Copyright © 2014 by the International Association for the Study of Lung Cancer
ISSN
1556-0864
DOI
10.1097/JTO.0000000000000174
pmid
25157781
Publisher site
See Article on Publisher Site

Abstract

Case Repotr LDK378 Compassionate Use for Treating  Carcinomatous Meningitis in an ALK Translocated  Non–Small-Cell Lung Cancer Jennifer Arrondeau,* Samy Ammari,† Benjamin Besse,‡ and Jean-Charles Soria§ 42-year-old woman, never smoker, complaining of chronic treated with crizotinib. Crizotinib is a potent, small molecule Acough, underw   ent computed tomography that depicted oral inhibitor of ALK, which has shown efficacy in ALK- a right lower lung mass and subcarinal lymphadenopathy. rearranged NSCLC with an overall response rate (ORR) of Disease was classified as stage IIIA lung adenocarcinoma 60.8% and a median progression-free survival duration of 9.7 2 3 (cT3N2M0), without an EGFR or KRAS mutation. After neo- months. ORR to crizotinib is only 25% in brain metastasis. adjuvant chemotherapy with cisplatin and gemcitabine, the The central nervous system (CNS) remains the dominant site patient underwent surgery comprising a right pneumonectomy of acquired resistance on therapy for ALK patients with or and a lymph node dissection. One year and a half later, she was without brain metastasis. LDK378 (Novartis) is a new potent diagnosed with liver metastasis. The patient was treated with and selective oral ALK inhibitor. Tumor regression has been carboplatin, pemetrexed, and bevacizumab, achieving a stable observed in ALK-positive NSCLC xenografts and even in disease for 9 months. Fluorescence in situ hybridization

Journal

Journal of Thoracic OncologyWolters Kluwer Health

Published: Aug 1, 2014

There are no references for this article.